Hadean Ventures | Activity

Investment

Led Kasvu Therapeutics' EUR 30M Series A to advance its TrkB potentiator into clinical development for neuropsychiatric disorders.

Kasvu Therapeutics

Kasvu Therapeutics Hadean Ventures

hadeanventures.comSEP 24, 2026

Milestone

Neuro Event Labs received CMS New Technology Add-On Payment (NTAP) approval for its Nelli seizure monitoring system.

Neuro Event Labs

Neuro Event Labs Hadean Ventures

hadeanventures.comSEP 4, 2026

SEP 4, 2026

Milestone

Complement Therapeutics completed Cohort 2 dosing with a favourable IDMC recommendation to proceed to high-dose and expansion cohorts in the Phase I/II Opti-GAIN study.

Complement Therapeutics

Complement Therapeutics Hadean Ventures

hadeanventures.comSEP 1, 2026

SEP 1, 2026

Milestone

TargED announced first patients successfully dosed in a study of TGD001 in acute ischemic stroke.

TargED Biopharmaceuticals

TargED Biopharmaceuticals Hadean Ventures

hadeanventures.comJUL 16, 2026

JUL 16, 2026

Investment

Led TargED's EUR 40.4M Series A2 to advance the first-in-class targeted thrombolytic TGD001.

TargED Biopharmaceuticals

TargED Biopharmaceuticals Hadean Ventures

hadeanventures.comJUN 24, 2026

JUN 24, 2026

Milestone

Oncoinvent achieved a 50% recruitment milestone in its Phase 2 ovarian cancer study of Radspherin.

Oncoinvent

Oncoinvent Hadean Ventures

hadeanventures.comJUN 18, 2026

JUN 18, 2026

Milestone

Gesynta Pharma randomized 50% of patients in its Phase 2 endometriosis trial of vipoglanstat.

Gesynta Pharma

Gesynta Pharma Hadean Ventures

hadeanventures.comJUN 17, 2026

JUN 17, 2026

Milestone

Complement Therapeutics completed Cohort 1 dosing with a favourable IDMC recommendation in the Phase I/II Opti-GAIN study.

Complement Therapeutics

Complement Therapeutics Hadean Ventures

hadeanventures.comMAY 27, 2026

MAY 27, 2026

Milestone

First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat.

Gesynta Pharma

Gesynta Pharma Hadean Ventures

hadeanventures.comMAR 11, 2026

MAR 11, 2026

Milestone

Neuro Event Labs received FDA 510(k) clearance for the Nelli seizure monitoring system.

Neuro Event Labs

Neuro Event Labs Hadean Ventures

hadeanventures.comNOV 25, 2025

NOV 25, 2025

Investment

Step Pharma completed a EUR 38 million Series C financing.

STEP Pharma

STEP Pharma Hadean Ventures

hadeanventures.comOCT 15, 2025

OCT 15, 2025

Investment

ARTHEx Biotech upsized its Series B financing round to $87M to advance ATX-01 in myotonic dystrophy type 1.

ARTHEx Biotech

ARTHEx Biotech Hadean Ventures

hadeanventures.comSEP 17, 2025

SEP 17, 2025

Investment

Gesynta Pharma announced second closing of its Series B, now totaling SEK 347M, with HealthCap and Hadean Growth Fund joining the investor syndicate.

Gesynta Pharma

Gesynta Pharma Hadean Ventures

hadeanventures.comAUG 5, 2025

AUG 5, 2025

Exit

Portfolio company Abliva was acquired by Pharming Technologies via a completed cash offer to shareholders.

Abliva

Abliva Hadean Ventures

hadeanventures.comFEB 25, 2025

FEB 25, 2025

Hadean Ventures Activity

Led Kasvu Therapeutics' EUR 30M Series A to advance its TrkB potentiator into clinical development for neuropsychiatric disorders.

Neuro Event Labs received CMS New Technology Add-On Payment (NTAP) approval for its Nelli seizure monitoring system.

Complement Therapeutics completed Cohort 2 dosing with a favourable IDMC recommendation to proceed to high-dose and expansion cohorts in the Phase I/II Opti-GAIN study.

TargED announced first patients successfully dosed in a study of TGD001 in acute ischemic stroke.

Led TargED's EUR 40.4M Series A2 to advance the first-in-class targeted thrombolytic TGD001.

Oncoinvent achieved a 50% recruitment milestone in its Phase 2 ovarian cancer study of Radspherin.

Gesynta Pharma randomized 50% of patients in its Phase 2 endometriosis trial of vipoglanstat.

Complement Therapeutics completed Cohort 1 dosing with a favourable IDMC recommendation in the Phase I/II Opti-GAIN study.

First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat.

Neuro Event Labs received FDA 510(k) clearance for the Nelli seizure monitoring system.

Step Pharma completed a EUR 38 million Series C financing.

ARTHEx Biotech upsized its Series B financing round to $87M to advance ATX-01 in myotonic dystrophy type 1.

Gesynta Pharma announced second closing of its Series B, now totaling SEK 347M, with HealthCap and Hadean Growth Fund joining the investor syndicate.

Portfolio company Abliva was acquired by Pharming Technologies via a completed cash offer to shareholders.